fingolimod hydrochloride has been researched along with Atherosclerotic Parkinsonism in 2 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 2 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Dagli, TC; Falkenburger, BH; Habib, P; Komnig, D; Schulz, JB; Zeyen, T | 1 |
| Diaz-Pacheco, V; Gil-Tommee, C; Miranda, JD; Najera, K; Perez, RG; Vargas-Medrano, J; Vidal-Martinez, G; Yang, B | 1 |
2 other study(ies) available for fingolimod hydrochloride and Atherosclerotic Parkinsonism
| Article | Year |
|---|---|
Fingolimod (FTY720) is not protective in the subacute MPTP mouse model of Parkinson's disease and does not lead to a sustainable increase of brain-derived neurotrophic factor.
Topics: alpha-Synuclein; Animals; Antiparkinson Agents; Brain-Derived Neurotrophic Factor; Dopamine; Dopaminergic Neurons; Fingolimod Hydrochloride; Humans; Immunohistochemistry; Mice; Mice, Inbred C57BL; Mice, Transgenic; MPTP Poisoning; Negative Results; Neuroprotective Agents; Parkinson Disease, Secondary; Substantia Nigra | 2018 |
FTY720 Improves Behavior, Increases Brain Derived Neurotrophic Factor Levels and Reduces α-Synuclein Pathology in Parkinsonian GM2+/- Mice.
Topics: alpha-Synuclein; Animals; Behavior, Animal; Brain; Brain-Derived Neurotrophic Factor; Fingolimod Hydrochloride; Mice; Mice, Transgenic; Motor Skills; N-Acetylgalactosaminyltransferases; Parkinson Disease, Secondary; Rotarod Performance Test; Sphingosine 1 Phosphate Receptor Modulators | 2019 |